BIORBIORA THERAPEUTICS, INC.

Nasdaq bioratherapeutics.com


$ 1.10 $ -0.07 (-5.98 %)    

Thursday, 28-Mar-2024 15:59:40 EDT
QQQ $ 443.93 $ -0.82 (-0.18 %)
DIA $ 397.72 $ 0.20 (0.05 %)
SPY $ 523.07 $ -0.10 (-0.02 %)
TLT $ 94.55 $ -0.08 (-0.08 %)
GLD $ 205.72 $ 2.62 (1.29 %)
$ 1.1
$ 1.10
$ 0.00 x 0
$ 0.00 x 0
$ 1.09 - $ 1.11
$ 0.76 - $ 6.70
357,256
na
16.53M
$ 1.67
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-13-2023 09-30-2023 10-Q
2 08-14-2023 06-30-2023 10-Q
3 05-15-2023 03-31-2023 10-Q
4 03-30-2023 12-31-2022 10-K
5 11-14-2022 09-30-2022 10-Q
6 08-15-2022 06-30-2022 10-Q
7 05-10-2022 03-31-2022 10-Q
8 03-28-2022 12-31-2021 10-K
9 11-10-2021 09-30-2021 10-Q
10 08-12-2021 06-30-2021 10-Q
11 05-13-2021 03-31-2021 10-Q
12 03-18-2021 12-31-2020 10-K
13 11-09-2020 09-30-2020 10-Q
14 08-14-2020 06-30-2020 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 biora-therapeutics-q4-eps-063-misses-059-estimate

Biora Therapeutics (NASDAQ:BIOR) reported quarterly losses of $(0.63) per share which missed the analyst consensus estimate of ...

 earnings-scheduled-for-march-26-2024

Companies Reporting Before The Bell • bluebird bio (NASDAQ:BLUE) is likely to report quarterly loss at $0.66 per share on reve...

 biora-therapeutics-further-reduces-net-debt-convertible-notes-exchange-brings-in-another-28m-in-new-capital-and-announces-monetization-of-legacy-asset-brings-in-3m-in-nondilutive-capital

Monetization of legacy asset brings in $3 million in nondilutive capital Convertible notes exchange brings in another $2.8 mill...

 why-helix-energy-solutions-shares-are-trading-lower-by-11-here-are-other-stocks-moving-in-tuesdays-mid-day-session

Shares of Helix Energy Solutions Group, Inc. (NYSE: HLX) fell sharply during Tuesday’s session following weak earnings.

 why-4d-molecular-therapeutics-shares-are-trading-higher-by-20-here-are-20-stocks-moving-premarket

Shares of 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) rose sharply in today’s pre-market trading. 4DMT presented interim da...

 biora-therapeutics-provides-guidance-on-anticipated-milestones-during-2024-says-we-begin-2024-in-the-clinic-with-our-phase-1-study-for-bt-600-which-will-be-a-major-de-risking-step-in-the-development-of-our-navicap-platform

Biora Therapeutics, Inc. (NASDAQ:BIOR), the biotech company that is reimagining therapeutic delivery, today provided guidance o...

 biora-therapeutics-announces-initiation-of-phase-1-clinical-study-of-bt-600-first-in-human-trial-of-bt-600-drug-device-combination-following-multiple-successful-device-only-human-studies

First-in-human trial of BT-600 drug-device combination, following multiple successful device-only human studies SAD/MAD study t...

 why-dermata-therapeutics-shares-are-trading-higher-by-over-57-here-are-20-stocks-moving-premarket

Shares of Dermata Therapeutics, Inc. (NASDAQ: DRMA) rose sharply in pre-market trading after the company announced the issuan...

 hc-wainwright--co-reiterates-buy-on-biora-therapeutics-maintains-50-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Biora Therapeutics (NASDAQ:BIOR) with a Buy and maintains $50 pr...

Core News & Articles

Biora Therapeutics, Inc. (NASDAQ:BIOR), the biotech company that is reimagining therapeutic delivery, today announced that its ...

 biora-therapeutics-announces-new-patent-for-its-navicap-targeted-oral-delivery-platform

Biora Therapeutics, Inc. (NASDAQ:BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it r...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION